ArticleThe journal of allergy and clinical immunology. In practice
Predictive Properties of the Asthma Control Test and Its Component Questions for Severe Asthma Exacerbations.
Article in The journal of allergy and clinical immunology. In practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Screening Tools in School-Based Health Centers for Children With Asthma.The Journal of school health · 2025Trial
- Can digital communication technology reduce health system personnel time? An evaluation of personnel requirements and costs in a randomized controlled trial.Translational behavioral medicine · 2021Trial
- Artificial intelligence-assisted clinical decision support for childhood asthma management: A randomized clinical trial.PloS one · 2021Trial
- Trial
- Early benefit of mepolizumab on small airways in severe asthma: insights from the IMPOSE study.ERJ open research · 2025Article
- Review
- Clinical features in patients with COVID-19 treated with biologics for severe asthma.The journal of allergy and clinical immunology. Global · 2024Article
- Prediction of Asthma Exacerbations in Children.Journal of personalized medicine · 2023Review
- D-ROMs and PAT Tests Reveal a High Level of Oxidative Stress in Patients with Severe Well-Controlled Asthma, and D-ROMs Are Positively Correlated with R20 Values That Indicate Approximate Central Airway Resistance.Journal of personalized medicine · 2023Article
- Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center.Biomedicines · 2022Article
- Is overreliance on short-acting βERJ open research · 2022Article
- Relationship between the Asthma Control Test (ACT) and other outcomes: a targeted literature review.BMC pulmonary medicine · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundCurrent US guidelines recommend the Asthma Control Test (ACT) for assessing disease control and selecting treatment.
objectiveThe goal of this study was to prospectively assess the ACT and its component questions for their utility in predicting the risk of severe asthma exacerbations.
methodsIndividuals were participants in the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity, and those included in the current analysis had the following characteristics: age 18 years or more, physician-diagnosed asthma, and longitudinal care received at a large health system in southeastern Michigan. Study participants underwent a baseline evaluation, which included answering the ACT. A severe asthma exacerbation was defined as one requiring oral steroids, an emergency department visit, or inpatient admission. Receiver-operator characteristic curves were used to measure and compare the predictive utility of the ACT and its component questions for severe asthma exacerbations.
resultsOf 1180 participants, 354 (30.0%) experienced a severe asthma exacerbation within 6 months of their baseline evaluation. When compared with the individual questions that composed the ACT, the composite score was significantly better at predicting severe exacerbations with 1 exception; the composite ACT score and the question assessing rescue medication use were not significantly different (P = .580). Pharmacy-based records of metered-dose inhaler short-acting beta-agonist use and asthma severity were also not significantly different from the composite ACT score.
conclusionsOur study demonstrates that although the ACT is modestly predictive for exacerbations, the composite score may not be superior to assessing rescue medication use alone for predicting the risk of severe asthma exacerbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.